Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis

NCT01814475 is registered in ClinicalTrials.gov with Gruppo Italiano Trapianto di Midollo Osseo as lead sponsor.

NCT NCT01814475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01814475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis
Lead sponsor
Gruppo Italiano Trapianto di Midollo Osseo
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2011
Completion date
December 31, 2016
Enrollment
62 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis